General MedicationsINJECTIONStandard
ZIIHERA
ZANIDATAMAB-HRII
Standard Dose
300MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: PRIORITY Marketing status: Prescription
Summary
Approval overview ZIIHERA is listed in Drugs@FDA under application 761416 (BLA).
Review priority: PRIORITY Marketing status: Prescription Active ingredient ZANIDATAMAB-HRII Form and strength INJECTABLE;INJECTION - 300MG Sponsor JAZZ PHARMS Submission history Latest submission status date: 2024-11-20 00:00:00.
Structured Monograph
Clinical summary
Approval overview ZIIHERA is listed in Drugs@FDA under application 761416 (BLA). Review priority: PRIORITY Marketing status: Prescription Active ingredient ZANIDATAMAB-HRII Form and strength INJECTABLE;INJECTION - 300MG Sponsor JAZZ PHARMS Submission history Latest submission status date: 2024-11-20 00:00:00. Submission type: ORIG.
Monitoring
- • Marketing status: Prescription
- • Review priority: PRIORITY
Interaction Notes
- No interaction notes stored yet.